In our study, over 75% of patients with TFH-TCL, PTCL-NOS, and ATLL were CD5+ at the initial presentation, justifying that these CD5-directed adoptive cell therapies have the potential to significantly improve the outcomes of TCL patients. Here, CD5 is linked to adult T-cell leukemia/lymphoma.